REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2017

Jan 13, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2017-01-11

Reporting Person: Sanofi (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-01-11	Common Stock	P	1592	$362.4664	Acquired	23419988	Indirect
2017-01-11	Common Stock	P	6546	$363.3534	Acquired	23426534	Indirect
2017-01-11	Common Stock	P	13226	$364.3224	Acquired	23439760	Indirect
2017-01-11	Common Stock	P	19858	$365.2018	Acquired	23459618	Indirect
2017-01-11	Common Stock	P	3979	$366.0528	Acquired	23463597	Indirect
2017-01-11	Common Stock	P	1986	$367.2911	Acquired	23465583	Indirect
2017-01-11	Common Stock	P	2336	$368.3472	Acquired	23467919	Indirect
2017-01-11	Common Stock	P	2517	$369.3	Acquired	23470436	Indirect
2017-01-11	Common Stock	P	900	$370.1789	Acquired	23471336	Indirect
2017-01-11	Common Stock	P	1259	$371.5346	Acquired	23472595	Indirect
2017-01-11	Common Stock	P	2675	$372.8741	Acquired	23475270	Indirect
2017-01-11	Common Stock	P	2784	$373.9018	Acquired	23478054	Indirect
2017-01-11	Common Stock	P	3830	$374.5922	Acquired	23481884	Indirect
2017-01-11	Common Stock	P	3016	$375.8789	Acquired	23484900	Indirect
2017-01-11	Common Stock	P	3851	$376.7488	Acquired	23488751	Indirect
2017-01-11	Common Stock	P	5313	$377.8368	Acquired	23494064	Indirect
2017-01-11	Common Stock	P	9520	$378.7635	Acquired	23503584	Indirect
2017-01-11	Common Stock	P	2110	$379.5636	Acquired	23505694	Indirect

Footnotes

F1: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.

F2: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN").

F3: Purchase prices range from $361.76 to $362.71 per share, inclusive.

F4: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,706,142 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors.

F5: Purchase prices range from $362.80 to $363.79 per share, inclusive.

F6: Purchase prices range from $363.80 to $364.77 per share, inclusive.

F7: Purchase prices range from $364.80 to $365.79 per share, inclusive.

F8: Purchase prices range from $365.80 to $366.73 per share, inclusive.

F9: Purchase prices range from $366.83 to $367.81 per share, inclusive.

F10: Purchase prices range from $367.84 to $368.78 per share, inclusive.

F11: Purchase prices range from $368.84 to $369.79 per share, inclusive.

F12: Purchase prices range from $369.87 to $370.59 per share, inclusive.

F13: Purchase prices range from $371.05 to $372.02 per share, inclusive.

F14: Purchase prices range from $372.29 to $373.27 per share, inclusive.

F15: Purchase prices range from $373.30 to $374.28 per share, inclusive.

F16: Purchase prices range from $374.31 to $375.24 per share, inclusive.

F17: Purchase prices range from $375.36 to $376.34 per share, inclusive.

F18: Purchase prices range from $376.36 to $377.34 per share, inclusive.

F19: Purchase prices range from $377.36 to $378.35 per share, inclusive.

F20: Purchase prices range from $378.37 to $379.36 per share, inclusive.

F21: Purchase prices range from $379.38 to $379.80 per share, inclusive.